RxDoctor Payments Data

Katie Evans

Foot & Ankle Surgery · Virginia, MNNPI 1114351376

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (42.6%), food and beverage and education — rather than concentrated in one kind of arrangement. Stryker accounts for 76.6% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $5,971 and has fallen 64.4% since, to $2,128 in 2025.

$14,007in general payments, 2019–2025

Across 119 payments — averaging $117.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$11K
  • Arthrosurface Incorporated$3K
  • Organogenesis Inc.$198
  • Kerecis Limited$124
  • Integra Lifesciences Corporation$52
  • Treace Medical Concepts, Inc.$43
  • plus $154 from 7 others

What the payments were for

  • Speaking & faculty fees$1,50011%
  • Travel & lodging$5,97143%
  • Food & beverage$3,68926%
  • Education$2,84720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,007 in reported general payments places this provider in the 85th percentile of 102 foot & ankle surgery providers in Minnesota.

See all foot & ankle surgery providers in Minnesota

Medicare billing

Part B allowed, 2024
$69,555
Medicare patients
283
Services billed
1,313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.11$3,848
SsdSilver Sulfadiazine37$291
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$167
Silver Sulfadiazine25$152
Meloxicam36$125
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen21$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$28$3,84811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 102 foot & ankle surgery providers in Minnesota.

Other foot & ankle surgery in Virginia

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →